{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:38:11Z","timestamp":1648651091858},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00393-006-0085-9","type":"journal-article","created":{"date-parts":[[2006,8,21]],"date-time":"2006-08-21T13:29:57Z","timestamp":1156166997000},"page":"378-382","source":"Crossref","is-referenced-by-count":1,"title":["Der niereninsuffiziente Osteoporosepatient: Was ist bei der osteoprotektiven Medikation zu beachten?"],"prefix":"10.1007","volume":"65","author":[{"given":"G.","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"85_CR1","first-page":"Bartl","volume":"In","author":"Bartl","year":"2006","unstructured":"Bartl R, Treschkow E v, Bartl C (2006) Bisphosphonate In: Bartl R, Treschkow E v, Bartl C (Hrsg) Bisphosphonat-Manual \u2013Wirkungen, Indikationen, Strategien. Springer, Berlin Heidelberg New York Tokyo, S 41\u201393","journal-title":"Bisphosphonate"},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitser MR et al. (2004) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399\u20131405","journal-title":"Ann Oncol"},{"key":"85_CR3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","volume":"111","author":"Desikan","year":"2002","unstructured":"Desikan R, Veksler Y, Raza S (2002) Nephrotic proteinuria associated with high dose pamidronate in multiple myeloma. Br J Haematol 111: 496\u2013499","journal-title":"Br J Haematol"},{"key":"85_CR4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/jbmr.5650101122","volume":"10","author":"Ensrud","year":"1995","unstructured":"Ensrud KE, Palermo L, Black DM et al. (1995) Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 10: 1778\u20131787","journal-title":"J Bone Miner Res"},{"key":"85_CR5","first-page":"50","volume":"31","author":"Heidenreich","year":"2005","unstructured":"Heidenreich A, Ohlmann C, Bergner R (2005) Renal safety of loading dose ibandronate in urologic patients with compensated renal insufficiency. Cancer Treat Rev 31 (Suppl 1): 50","journal-title":"Cancer Treat Rev"},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","volume":"63","author":"Hernandez","year":"2003","unstructured":"Hernandez E, Valera R, Alonzo E et al. (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63: 2269\u20132274","journal-title":"Kidney Int"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003495-199753030-00006","volume":"53","author":"Jeal","year":"1997","unstructured":"Jeal W, Barradell L B, McTavish D (1997) Alendronate a review of its pharmacological and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53: 415\u2013434","journal-title":"Drugs"},{"key":"85_CR8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF Jr et al. (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14: 570\u2013576","journal-title":"Osteoporos Int"},{"key":"85_CR9","first-page":"17","volume":"10","author":"Lhotta","year":"2006","unstructured":"Lhotta K, Mayer G, Kronenberg F (2006) Nutzen und Problematik der MDRD-Formel. Dialyse aktuell 10: 17\u201322","journal-title":"Dialyse aktuell"},{"key":"85_CR10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0272-2712(18)30474-8","volume":"13","author":"Lindemann","year":"1993","unstructured":"Lindemann RD (1993) Assessment of renal funktion in the old. Special considerations. Clin Lab Med 13: 269\u2013277","journal-title":"Clin Lab Med"},{"key":"85_CR11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"Lindemann","year":"1985","unstructured":"Lindemann RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33: 278\u2013285","journal-title":"J Am Geriatr Soc"},{"key":"85_CR12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164\u20131172","journal-title":"J Am Soc Nephrol"},{"key":"85_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650100202","volume":"10","author":"Melton","year":"1995","unstructured":"Melton LJ III (1995) How many women have osteoporosis now? J Bone Miner Res 10: 175\u2013177","journal-title":"J Bone Miner Res"},{"key":"85_CR14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"Miller","year":"2005","unstructured":"Miller P, Roux C, Boonen S et al. (2005) Safety and efficacy of Risedronat in patients with age-related reduced renal function as estimated by the Cockcoft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20: 2105\u20132115","journal-title":"J Bone Miner Res"},{"key":"85_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.10-90001-19","volume":"10","author":"Moos","year":"2005","unstructured":"Moos R v (2005) Bisphosphonate treatment recommendations for oncologists. Oncologist 10 (Suppl 1): 19\u201324","journal-title":"Oncologist"},{"key":"85_CR16","unstructured":"National Osteoporosis Foundation Medications to prevent and treat osteoporosis. Available at http:\/\/www.nof.org\/patientinfo\/medications.htm. Assesed April 16.2005"},{"key":"85_CR17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785\u2013795","journal-title":"JAMA"},{"key":"85_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1358\/dot.2003.39.2.799416","volume":"39","author":"Reginster","year":"2003","unstructured":"Reginster JY, Deroisy R, Jupsin I (2003) Strontiumranelate a new paradigm in the treatment of osteoporosis. Drugs Today 39: 89\u2013101","journal-title":"Drugs Today"},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","volume":"47","author":"Sauter","year":"2006","unstructured":"Sauter M, J\u00fclg B, Porubsky S et al. (2006) Nephrotic-range proteinuria following Pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47: 1075\u20131080","journal-title":"Am J Kidney Dis"},{"key":"85_CR20","unstructured":"US Prescribing Information Forteo. Available at: http:\/\/www.forteo.com"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0085-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-006-0085-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0085-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T15:01:45Z","timestamp":1627743705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-006-0085-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1007\/s00393-006-0085-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}